Clinical Practice Guidelines for the Management of Congenital Cytomegalovirus Infection in Japan 2023: Executive Summary
Author:
Ito YoshinoriORCID, Morioka Ichiro1, Takahashi Naoto1, Fujioka Kazumichi1, Miura Kiyonori1, Moriuchi Hiroyuki1, Morimoto Noriko1, Yoshikawa Tetsushi1, Ashina Mariko1, Abe Shinya1, Imafuku Hitomi1, Uchida Akiko1, Okahashi Aya1, Kakiuchi Satsuki1, Kakimoto Yu1, Kawata Soichiro1, Kawamura Yoshiki1, Kido Takumi1, Kidokoro Hiroyuki1, Kozawa Kei1, Samejima Tomohiro1, Suzuki Takako1, Tanimura Kenji1, Tomonaga Chiharu1, Torii Yuka1, Nakanishi Megumi1, Nagano Nobuhiko1, Nagamatsu Takeshi1, Narita Hajime1, Nishimura Koji1, Nonobe Norie1, Hasegawa Yuri1, Hara Koichiro1, Hijikata Midori1, Fukuda Takuya1, Funato Yusuke1, Mimura Nobuko1, Yamamoto Nobuko1, Yoshitomi Ai1, Kakei Yasumasa1, Kodama Tomoyuki1, Oka Akira1
Affiliation:
1. From the Committee on Clinical Practice Guidelines for the Management of Congenital Cytomegalovirus Infection in Japan, Tokyo, Japan.
Abstract
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection in developed countries. Although a standard therapy has not yet been established, evidence for the management of cCMV infection has been accumulating. The first edition of the “Clinical Practice Guidelines for the Management of Congenital Cytomegalovirus Infection” was published in Japan in 2023. This summary outlines the clinical questions (CQs) in the guidelines, with reference to the Japanese Medical Information Distribution Service Manual. Overall, 20 CQs with statements regarding prenatal risk assessment, prevention and management at diagnosis (CQs 1-1–1-3), diagnosis (CQs 2-1–2-6), treatment (CQs 3-1–3-7) and follow-up requirements (CQs 4-1–4-4) have been discussed. For each statement, the levels of recommendation, evidence and consensus rates were determined. These guidelines will assist in the management of patients with cCMV infection.
Publisher
Ovid Technologies (Wolters Kluwer Health)
|
|